Advances in Payload and Linker Designs for ADCs

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a targeted cancer therapy approach.
• ADCs have evolved through multiple generations, with recent focus on novel drug payloads, linkers, and conjugation chemistries.
• Physicochemical properties like hydrophobicity and payload release significantly impact ADC efficacy and toxicity.

Purpose of the Study:

• To review recent advancements in Antibody-drug conjugate (ADC) technology.
• To highlight novel payloads, linker strategies, and conjugation chemistries.
• To discuss emerging trends in ADC development for improved cancer treatment.

Main Methods:

• Literature review of recent advancements in Antibody-drug conjugate (ADC) research.
• Analysis of novel drug payloads, linker technologies, and conjugation methods.
• Discussion of physicochemical properties influencing ADC performance.

Main Results:

• Recent ADC development focuses on new drug modalities (immune-stimulators, degraders, radionuclides, photosensitizers) and dual-payload strategies.
• Linker modifications are key to enhancing ADC stability, drug-to-antibody ratio (DAR), and controlled payload release.
• Site-specific conjugation and improved chemistries are crucial for optimizing ADC properties.

Conclusions:

• Advancements in payloads and linkers are enhancing the therapeutic index of ADCs.
• Novel strategies aim to improve targeted delivery and payload release at the tumor site.
• Continued innovation in ADC technology promises more effective and safer cancer therapies.